- Home
- BJRI vs CRVS Comparison
BJRI vs CRVS Comparison
Compare BJRI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | CRVS |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BJRI | CRVS |
|---|---|---|
| Price | $60.94 | $13.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $42.88 | $30.17 |
| AVG Volume (30 Days) | 417.6K | ★ 645.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 208.57 | 48.04 |
| EPS | ★ 1.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $3.89 | N/A |
| P/E Ratio | $47.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.46 | $5.64 |
| 52 Week High | $74.60 | $26.95 |
Technical Indicators
Market Signals| Indicator | BJRI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 45.80 |
| Support Level | $40.72 | $12.76 |
| Resistance Level | $62.07 | $14.00 |
| Average True Range (ATR) | 2.58 | 0.61 |
| MACD | -0.81 | -0.07 |
| Stochastic Oscillator | 27.95 | 13.20 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.